Date published: 2025-12-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

NOD9 Inhibitors

NOD9 Inhibitors are compounds that, while not directly inhibiting NOD9 (NLRX1), can influence its activity indirectly. These compounds primarily affect cellular stress responses or the innate immune response, thereby influencing the function of NLRX1. For instance, Cyclosporine A and FK506 are immunosuppressants that inhibit the calcineurin pathway. As NLRX1 plays a role in the innate immune response, these compounds can indirectly inhibit NLRX1. Conversely, compounds like PD98059, SP600125, SB203580, BAY 11-7082, LY294002, Wortmannin, and Rapamycin inhibit various parts of the MAPK and PI3K/AKT/mTOR pathways. Given NLRX1's role in modulating these pathways, these compounds can trigger its inhibition. Other compounds like Mdivi-1, 2-Deoxy-D-glucose, and Z-VAD-FMK disrupt mitochondrial function, inhibit glycolysis, or inhibit apoptosis, respectively.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Cyclosporin A

59865-13-3sc-3503
sc-3503-CW
sc-3503A
sc-3503B
sc-3503C
sc-3503D
100 mg
100 mg
500 mg
10 g
25 g
100 g
$62.00
$90.00
$299.00
$475.00
$1015.00
$2099.00
69
(5)

Cyclosporine A is an immunosuppressant that inhibits the calcineurin pathway. Given NLRX1's role in the innate immune response, this could lead to its inhibition.

FK-506

104987-11-3sc-24649
sc-24649A
5 mg
10 mg
$76.00
$148.00
9
(1)

FK506 is an immunosuppressant that inhibits the calcineurin pathway. Like Cyclosporine A, this could lead to the inhibition of NLRX1.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

PD98059 is a selective inhibitor of MEK, which is upstream of ERK in the MAPK pathway. NLRX1 can modulate this pathway, so PD98059 may indirectly inhibit NLRX1.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is a selective inhibitor of JNK, part of the MAPK pathway. Given NLRX1's role in modulating this pathway, SP600125 could potentially inhibit NLRX1.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

SB203580 inhibits p38, another part of the MAPK pathway. This could potentially lead to the inhibition of NLRX1.

BAY 11-7082

19542-67-7sc-200615B
sc-200615
sc-200615A
5 mg
10 mg
50 mg
$61.00
$83.00
$349.00
155
(1)

BAY 11-7082 inhibits the activation of NF-κB. As NLRX1 can modulate this pathway, BAY 11-7082 could potentially inhibit NLRX1.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 is a potent inhibitor of PI3K, a key regulator in the AKT/mTOR pathway. Given NLRX1's role in modulating cellular stress responses, this could lead to its inhibition.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin is another potent inhibitor of PI3K. Like LY294002, this could potentially lead to the inhibition of NLRX1.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

While Rapamycin is known to inhibit mTOR, it can have complex effects on cellular signaling and can potentially inhibit NLRX1.

Mdivi-1

338967-87-6sc-215291
sc-215291B
sc-215291A
sc-215291C
5 mg
10 mg
25 mg
50 mg
$66.00
$124.00
$246.00
$456.00
13
(2)

Mdivi-1 inhibits mitochondrial division, which can disrupt mitochondrial function. Given NLRX1's association with mitochondria, this could potentially inhibit it.